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The N-terminal Region of the Atypical Chemokine Receptor
ACKR2 Is a Key Determinant of Ligand Binding*
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Kay D. Hewit, Alasdair Fraser, Robert J. B. Nibbs, and Gerard J. Graham1
From the Chemokine Research Group, Institute of Infection, Immunity and Inflammation, University of Glasgow,
Glasgow G12 8TA, United Kingdom
Background:ACKR2 is an atypical chemokine receptor that is biologically distinct fromconventional chemokine receptors.
Results: An N-terminal sulfated tyrosine motif is essential for ligand binding by ACKR2.
Conclusion: The structure/function basis for ligand binding by ACKR2 is similar to that of conventional chemokine receptors.
Significance: ACKR2 N-terminal peptides may be therapeutically useful as pan-chemokine blockers in inflammatory
pathologies.
The atypical chemokine receptor, ACKR2 is a pivotal regula-
tor of chemokine-driven inflammatory responses and works by
binding, internalizing, and degrading inflammatory CC-chemo-
kines.ACKR2displayspromiscuityof ligandbindingandiscapable
of interacting with up to 14 different inflammatory CC-chemo-
kines. Despite its prominent biological role, little is known about
the structure/function relationship within ACKR2, which regu-
lates ligand binding. Here we demonstrate that a conserved
tyrosinemotif at theN terminus ofACKR2 is essential for ligand
binding, internalization, and scavenging. In additionwedemon-
strate that sulfation of this motif contributes to ligand internal-
ization. Furthermore, a peptide derived from this region is capa-
ble of binding inflammatory chemokines and inhibits their
interaction with their cognate signaling receptors. Importantly,
the peptide is only active in the sulfated form, further confirm-
ing the importanceof the sulfated tyrosines for function. Finally,
we demonstrate that the bacterial protease, staphopain A, can
cleave the N terminus of ACKR2 and suppress its ligand inter-
nalization activity. Overall, these results shed new light on the
nature of the structuralmotifs inACKR2 that are responsible for
ligandbinding.The study alsohighlightsACKR2-derivedN-ter-
minal peptides as being of potential therapeutic significance.
Chemokines are the principal regulators of in vivo leukocyte
migration and are defined by the presence of variations on a
conserved cysteinemotif in their mature sequences (1), and the
large chemokine family is divided into four subfamilies (CC,
CXC, XC and CX3C) according to the specific nature of this
motif. Mammals have 45 chemokines and 18 receptors that
involve themselves, in sometimes very complex ways, in regu-
lating in vivo leukocyte migration. Given this complexity, it is
common to simplify chemokine, and chemokine receptor, biol-
ogy by referring to them as being either homeostatic or inflam-
matory according to the in vivo contexts inwhich they predom-
inantly function (2, 3). Thus chemokines involved in basal
trafficking of leukocytes into and out of peripheral tissues and
secondary lymphoid organs are referred to as homeostatic.
They are typically expressed at discrete tissue locales and by
discrete cell types. In contrast, inflammatory chemokines and
their receptors are largely involved in responding to tissue
insults, injuries, or infections. Inflammatory chemokines are
not expressed at high levels at steady state but are rapidly and
substantially transcriptionally activated following an inflamma-
tory insult. These chemokines then attract inflammatory leuko-
cytes bearing their cognate receptors, and these cells remove
pathogens, engulf debris, and assist in the process of tissue repair.
In addition to the 18 signaling receptors for chemokines (4),
there also exists a small subfamily of atypical chemokine recep-
tors (ACKRs)2 that are characterized by an inability to mount
classical receptor signaling following ligand binding (4–8).
This subfamily currently comprises four receptors namely the
Duffy antigen receptor for chemokines (DARC/ACKR1),
D6/ACKR2, CXCR7/ACKR3, and CCRL1/ACKR4. We have
been particularly interested in ACKR2, which was previously
known as D6 (5). This receptor binds essentially all inflamma-
tory CC-chemokines with high affinity but does not mount
classical signaling responses following ligand binding (9–11).
We and others have demonstrated that ACKR2 is a highly effi-
cient binder, internalizer, and scavenger of inflammatory CC-
chemokines (12, 13). In essence, therefore, ACKR2 plays a role
in removing chemokines from inflamed sites. ACKR2 is
expressed in barrier tissues including the skin, gut, and lung, as
well as in the syncytiotrophoblast layer of the placenta (14–16).
In adult tissues ACKR2 is prominently expressed on lymphatic
endothelial cells (16, 17), although expression has also been
reported on leukocytes (17–21) and keratinocytes (22). In keep-
ing with its chemokine scavenging role, numerous in vivo stud-
ies utilizing ACKR2-deficient mice have demonstrated the
fundamental importance of ACKR2 for the resolution of
inflammatory responses (15, 23–28). Although it was initially
assumed that this involved the scavenging and degradation of
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chemokines throughout an inflamed area, it now appears that
ACKR2 plays a more subtle role in this context by minimizing
inflammatory leukocyte interaction with lymphatic endothelial
cell surfaces and therefore ensuring the “openness” of lymphatic
channels (29–31). Thus in ACKR2-deficientmice, lymphatic ves-
sels become congested by inappropriate association with inflam-
matory leukocytes, and this impairs drainage of fluid, cytokines,
chemokines, and cells from inflamed sites thus accounting for the
impaired resolution of the inflammatory response.
Notably, despite having been clearly demonstrated to be
important in a range of in vivo contexts, little is known about
the structure/function relationships within ACKR2 that con-
tribute to chemokine binding. With the signaling chemokine
receptors, a number of regions are known to be involved in
ligand binding. Prominent among these is the N terminus and,
in particular, a sulfated tyrosine motif in this region (32–41,
43). The purpose of the present studywas to determinewhether
mechanisms important for chemokine interactions with con-
ventional chemokine receptors are conserved in the related
atypical receptor ACKR2.
In this study, we demonstrate the essential importance of
sulfated tyrosine residues at the N terminus of ACKR2 for
chemokine binding and internalization. In addition, we provide
evidence that a peptide generated from the N terminus of
ACKR2 is capable of neutralizing the in vitro activities of
ACKR2 ligands. These data therefore highlight the N terminus
as a key regulator of ligand binding by ACKR2 and suggest that
peptides derived from this region may have anti-inflammatory
therapeutic potential.
EXPERIMENTAL PROCEDURES
Antibodies—Antibodies used in this study, along with details
of suppliers, are listed in Table 1.
Cell Culture, Transfection, and PCR—HEK 293 cells were
maintained in DMEM (Sigma-Aldrich) plus 10% FCS, 4 mM
glutamine, and streptomycin and penicillin (all from Invitro-
gen). The human acute monocytic leukemia cell line, THP-1,
was maintained in RPMI 1640 (Sigma), 10% FCS, 4 mM gluta-
mine, and streptomycin and penicillin (all from Invitrogen). All
cultures were incubated at 37 °C with 5% CO2 and 95% humid-
ity. Human dermal-derived lymphatic endothelial cells (17),
human keratinocytes (22), BeWo (14) cells, CHO cells (17), and
monocytes (19) were cultured as described previously. Note
that transfected cell lines were used for themajority of the stud-
ies reported in this paper. The reasons for this were to ensure
consistency with the ACKR2 mutant data (which by necessity
had to be done in transfected cells) and because the primary
cells responsible for physiological expression of ACKR2 in vivo
are problematic. Specifically, lymphatic endothelial cells lose
ACKR2 expression in vitro (17), and the placental BeWo cell
line displays a lengthy doubling time (14), making the studies
we report impractical in this cell background.
Generation of Epitope-tagged Human ACKR2 (HA-ACKR2)
and RelatedMutants—Nucleotides encoding anN-terminal HA
tag (MYPYDVPDYAG) were introduced into human ACKR2
cDNA by PCR to generate HA-ACKR2 as described (44). Prod-
ucts were verified by sequencing (MWGOperon, London, UK)
and cloned into pcDNA3.1 (MWG Operon). The HA-ACKR2
pcDNA3.1 plasmid was mutated using the QuikChange light-
ning multisite-directed mutagenesis kit (Stratagene and Agi-
lent Technologies), and primers encoding tyrosine to phenyl-
alanine mutations were designed and used to generate point
mutations in the ACKR2 sequence (primers detailed in Table
2). All primers were from IDT (Interleuvenlaan, Belgium) and
were designed with the primer design guidelines detailed in the
kit instruction manual.
Generation of ACKR2 Transfected HEK 293 Cells—Plasmids
were stably transfected into HEK 293 cells using the Effectene
transfection reagent kit (Qiagen). Stable transfectants were
selected in 1.6 mg/ml G418 (Promega, Southampton, UK). High
ACKR2-expressing cells were separated from low expressing and
nonexpressing cells by adding anti-HA biotin (Miltenyi Biotec) to
cells and mixing with anti-biotin MicroBeads (Miltenyi Biotec).
Cells were run through MACS separation columns (Miltenyi
Biotec) attached to a MidiMACS separator (Miltenyi Biotec),
and eluates were collected. Expression of ACKR2 was verified
by flow cytometry using anti-ACKR2 monoclonal antibody
and FITC-labeled secondary antibody (R&D Systems) or
alternatively biotinylated anti-HA antibody (Miltenyi Bio-
tec) and phycoerythrin-streptavidin-labeled secondary anti-
body (R&D Systems).
Chemokine Uptake Assays—Either CCL2 or CCL22 (labeled
with Alexa Fluor 647: Alexa-CCL2 and Alexa-CCL22; Almac
Scotland, Edinburgh, UK) was added to cells. Cells were incu-
bated for different time periods at 37 °C in 5% CO2 and subse-
quentlywashed twice in ice-coldFACSbuffer.DRAQ7 (BioStatus,
Leicestershire, UK) was added to each cell suspension to iden-
tify nonviable cells. Fluorescence intensity of the cells was
acquired on a MACSquant analyzer (Miltenyi Biotec) and ana-
lyzed using MACSquant software.
Chemokine Degradation Assays—Cells were plated out the
night before the assay into a 96-well plate to80% confluency
(2  104 cells/well) in media. The following day, biotinylated
human CCL2 (bio-CCL2) (Almac) was added to the media at a
concentration of 50 g/ml, and cells were incubated at 37 °C in
5%CO2.Mediumwas collected at different time points ranging
from 0 to 30 h after the addition of bio-CCL2 and stored at
20 °C before being analyzed by Western blotting.
ImmunoprecipitationofHA-ACKR2andSulfotyrosineDetection—
HA-ACKR2was immunoprecipitated fromACKR2-expressing
TABLE 1
Antibodies used in this study
Antibody Supplier Use
Anti-HA tag antibody Abcam Flow cytometry
Anti Hu ACKR2 (clone 4A5) In house Western blotting
Anti-CCBP2 (ACKR2,
human)
Sigma Western blotting for detection
of N-terminal truncated
ACKR2
Anti-sulfotyrosine Millipore Western blotting
Anti-TPST1 (human) Abcam Western blotting
Anti-TPST2 (human) Abcam Western blotting
Anti--tubulin Cell Signalling Western blotting
Streptavidin-PE R&D Systems Western blotting
FITC-labeled anti-mouse R&D Systems Flow cytometry
Biotinylated mouse
IgG1-isotype control
R&D Systems Flow cytometry
Mouse IgG2a isotype control Dako Flow cytometry
Mouse IgG3 isotype control Amersham Flow cytometry
Anti-beta-actin Cell Signalling Western blotting
Characterizing a Ligand-bindingMotif in ACKR2
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HEK cells using theMACSTM epitope tag protein isolation kit
(Miltenyi Biotec) with anti-HA MicroBeads. Cell lysates were
prepared before magnetic labeling was performed by adding
anti-HA MicroBeads to the cell lysates and incubating for 30
min on ice with regular gentle agitation. The mixture was run
through a -column suspended on a magnet as per the man-
ufacturer’s instructions. After several washes to remove any
nonspecific material, elution buffer (SDS buffer) heated to
95 °C was added to the column, and samples were collected (cell
lysis buffer, wash buffer, and elution buffer are all supplied in the
Miltenyi Biotec kit). Subsequent to elution samples were analyzed
by SDS-PAGE beforeWestern blotting with an anti-sulfotyrosine
antibody (Millipore, Temecula, CA) or an anti-HA antibody
(Abcam, Cambridge, UK).
Treatment with Sodium Chlorate—Cells were grown in
media supplemented with a range of concentrations of sodium
chlorate (40) (Sigma) for various time periods before perform-
ing chemokine uptake assays as detailed above.
siRNA and ACKR2 Transfection—Cells were plated out the
night before in 6-well plates and grown to 80% confluency.
The following day cells were transfected with TPST-1 siRNA,
TPST-2 siRNA, or negative control siRNA using HiPerfect
transfection reagent (All from Qiagen). The next day, cells
were transiently transfected with the HA-ACKR2 plasmid
described above using the Effectene transfection reagent kit
(Qiagen). 24 h later cells were tested for their ability to uptake
AF-CCL22 using chemokine uptake assays. Cell lysates were
also collected and analyzed by Western blotting using an anti-
ACKR2 antibody (Sigma).
Quantitative PCR Analyses—Quantitative PCR was per-
formed as described previously (17, 19) using RT kitNanoscript
(PrimerDesign, Southampton, UK) and SYBR Green mix Per-
fecta (QuantaBioscience, Gaithersburg, MD). The following
primers were used: TPST 1 forward, 5-GCTGGGGGAGT-
GTCTCTGT-3; TPST 1 reverse, 5-TCCGTAGTTAGGTGGG-
TTGG-3; TPST 2 forward, 5-TCGGACCTCTAATCCAAGCA-
3; TPST 2 reverse, 5-TCCATACCCTTCATTCTCTACCC-3;
TBP forward, 5-TGCTGTTGGTGATTGTTGGT-3; TBP re-
verse, 5-AACTGGCTTGTGTGGGAAAG-3; ACKR2 forward,
5-AGGAAGGATGCAGTGGTGTC-3; and ACKR2 reverse,
5-CGGAGCAAGACCATGAGAAG-3.
Generation of ACKR2-N—Peptides representing the first
35 amino acids of the N terminus of the ACKR2 protein
(ACKR2-N) were generated by peptide synthesis (Almac Scot-
land). Two versions of ACKR2-N were generated, with either
sulfated or nonsulfated tyrosine residues. These are denoted as
ACKR2-N(s) and ACKR2-N(un-s) respectively. A hexahisti-
dine tag was incorporated into the C-terminal tail of both
ACKR2-N(s) and ACKR2-N(un-s).
Chemokine-ACKR2-N Binding Assays—Biotinylated chemo-
kines (Almac) were incubated with ACKR2-N(s), and the
MACSTM streptavidin kit (Miltenyi Biotec) was used to ascer-
tain any binding relationship between the twomolecules. Sam-
ples collected from such experiments were then run on SDS
gels and analyzed by Western blotting to examine any co-pull-
down of ACKR2-N.
SDS-PAGE—Samples were mixed 1:4 with NuPAGE LDS
sample buffer (Invitrogen) and either heated to 95 °C for 5 min
or, when analyzing ACKR2 expression, incubated at room tem-
perature for 10 min (44). Samples were mixed 1:10 with
NuPAGE sample reducing agent (Invitrogen). 10–20 l of
each sample was loaded onto a precast NuPAGENovex 4–12%
TABLE 2
Primers used for the generation of the ACKR2mutants
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Bis-Tris gel (Invitrogen) in a vertical electrophoresis tank (Xcell
Surelock; Invitrogen) filled with NuPAGE MES SDS running
buffer (Invitrogen). Novex Sharp prestained protein standard
(Invitrogen) was run alongside samples for size determination.
Electrophoresis was performed for 1–2 h at 150 V.
Western Blotting—Gels were transferred onto a nitrocellu-
lose membrane using an iBlot system (Invitrogen) according
to manufacturer’s instructions. Following transfer, the mem-
brane was washed in PBS Tween (PBST) and blocked in 5%
Milk/PBST either for 1–2 h at room temperature or overnight
at 4 °C. After blocking, the membrane was washed briefly in
PBST and incubated with primary antibody overnight at 4 °C.
The membrane was subsequently washed four times for 5 min
each in PBST and incubated with secondary antibody for 1 h at
room temperature. Blots were developed via a chemilumines-
cence reaction (SuperSignal WestPico kit; Pierce) before being
placed between acetate sheets and exposed to x-ray film
(Kodak, CarestreamHealth Inc., NewYork, NY) in a dark room
for varying time periods. Film was then developed in an
X-Omat processor (Konica-Minolta, Bainbury, UK).
Chemokine Uptake Assays with ACKR2-N as a Competitor—
Cells were treated as detailed previously; however, 1 g of
ACKR2-N(s) or ACKR2-N(un-s) (Almac) was added to wells
simultaneously with 60 ng/well of Alexa-CCL2 before incuba-
tion for 1 h at 37 °C in 5% CO2. In similar experiments Alexa-
CCL2 was “precomplexed” with ACKR2-N by incubating 1.0
g of ACKR2-N(s) or ACKR2-N(un-s) with 60 ng of Alexa-
CCL2 in a total volume of 20 l of PBS for 15 min at room
temperature before addition to wells. Cells were subsequently
analyzed on a MACSquant analyzer (Miltenyi Biotec).
Cleavage Assays with Staphopain A—Cells were plated out
the night before the assay into 6-well plates to about 80% con-
fluency (2 105 cells/well) in regular media. The following day
staphopainA (Sigma)was added to (2M) towells, and the cells
were incubated for various time periods ranging from 15min to
2 h at 37 °C in 5% CO2. Afterward cells were scraped, and cell
lysates were prepared using cell lysis buffer (Miltenyi Biotec).
Samples were then analyzed by Western blotting. For chemo-
kine uptake assays cells were washed twice with PBS before
scraping off and resuspending in complete medium and adding
25 nMAlexa-CCL22. Cells were incubated for 1 h at 37 °C in 5%
CO2 and subsequently washed twice in ice-cold FACS buffer.
DRAQ7 (BioStatus) was added to each cell suspension to iden-
tify nonviable cells. The fluorescence intensity of the cells was
measured on a MACSquant analyzer (Miltenyi Biotec).
Chemokine Fluorescence Assay Following Staphopain A
Treatment—Chinese hamster ovary (CHO) K1 cells expressing
ACKR2were plated out the night before on black 96-well plates
to80% confluency. The following day, cells were treated with
staphopain A (Sigma) in PBS at concentrations of 0.5 and 2 M
and incubated for 15min at 37 °C in 5%CO2. Cells werewashed
twice in PBS and put back into cell growthmedia supplemented
with 10% FCS. Alexa-CCL22 was added to the media at a con-
centration of 20 nM, and the cells were incubated at 37 °C in 5%
CO2 for 1 h. Cells were washed three times with PBS and then
analyzed on a PHERAstar FS fluorescence plate reader (BMG
Labtech). The raw data were analyzed using the integrated
MARS data analysis software (BMG Labtech).
Statistical Analyses—The data were analyzed using GraphPad
Prism (Version 5) software (San Diego, CA) with p 0.05 being
regardedas significant. Individual statistical tests used arenoted in
the relevant figure legends.
RESULTS
The ACKR2 N Terminus Bears a Conserved Tyrosine Motif
Involved in Ligand Binding—Alignment of the primary
sequences of the N terminus of ACKR2 from a variety of mam-
malian species (Fig. 1) revealed a highly conserved three-tyro-
sine motif that was commonly associated with neighboring
acidic amino acids. Such motifs are recognized sites of conven-
tional chemokine receptor sulfation and are important for
ligand binding (32–41, 43). Because we have previously shown
sulfation of ACKR2 (44), we tested the importance of this tyro-
sine motif for ligand binding by human ACKR2 using conven-
tionalmutagenesis. As shown in Fig. 2A, we generated amutant
version ofACKR2 (henceforth referred to asmutant 1) inwhich
all three conserved N-terminal tyrosine residues, as well as a
fourth unique to higher order primate ACKR2, within this
motif were mutated to phenylalanines. This construct was sta-
bly transfected into HEK cells and compared with HEK cells
expressing WT ACKR2 for ligand binding and internalizing
ability. Both molecules had an HA tag at the extreme N termi-
nus allowing for flow cytometric assessment of expression lev-
els in the stable clones. As shown in Fig. 2B, transfected HEK
cells expressed similar levels of cell surface WT ACKR2 and
mutant 1. Next we assessed the relative ability of WT ACKR2
andmutant 1 to internalize ligand by analyzing uptake ofAlexa-
CCL2 by flow cytometry. As shown in Fig. 2C, it is clear that
untransfected HEK cells do not internalize Alexa-CCL2 (Fig.
2C, panel i). However, whereas WT ACKR2 internalizes it
avidly (Fig. 2C, panel ii), similar uptake is not seen with mutant
FIGURE 1. Conservation of a tyrosine motif at the N terminus of ACKR2. Alignment of the N-terminal sequences from the named mammalian species is
shown. The tyrosine motif is highlighted in bold type, and the overall level of conservation at the N-terminal region of ACKR2 is shown in the last line.
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1 (Fig. 2C, panel iii). Indeed on multiple repeat experiments,
shown in Fig. 2D, it was clear that mutant 1 displayed a signifi-
cantly reduced ability to internalize ligand even at very high
chemokine concentrations. Finally, we examined the ability of
WT ACKR2 and mutant 1 to degrade ligand. As shown in Fig.
2E, whereas HEK cells expressing WT ACKR2 substantially
degraded biotinylated CCL2 over 24 h, as detected byWestern
blotting using a streptavidin detection system, two clones of
HEK cells expressing mutant 1 did not. Thus N-terminal tyro-
sine residues are essential contributors to the ability of ACKR2
to internalize and degrade chemokines.
Ligand Binding by ACKR2 Is Dependent on Receptor Sulfation—
The inability of the tyrosine mutant variant of ACKR2 to inter-
nalize ligand suggested that sulfation of these residues may, as
has been reported from conventional chemokine receptors, be
essential for ligand binding and uptake (32, 33, 35). We con-
firmed the reduction in sulfation in mutant 1 by Western blot-
ting of immunoprecipitated ACKR2 using an anti-tyrosylsul-
fate antibody. As shown in Fig. 3A, both a pool of mutant 1
transfected HEK cells and two separately isolated clones dis-
playedmarkedly reduced sulfation comparedwithWTACKR2.
Note that the low level staining seen in the mutant 1 tracks is
seen routinely, and thus we presume it to be background. To
further implicate sulfation in ligand internalization by ACKR2,
we incubated HEK cells expressing WT ACKR2 in 30 mM
sodium chlorate, which blocks protein sulfation, and assessed
the impact of this on ligand uptake. As analyzed by flow cytom-
etry and as shown in Fig. 3B, growth in the presence of sodium
chlorate partially but significantly reduced the ability of HEK
cells expressing ACKR2 to internalize ligand (in this case an
alternative ACKR2 ligand, Alexa-CCL22 was used) in a time-
dependent manner. To further examine the ability of sodium
FIGURE2.Deletionof the tyrosinemotif blocks ligand internalizationbyACKR2.A, inmutant 1, all the tyrosines in the identifiedmotif (labeled S to indicate
likely sulfation) have been mutated to phenylalanine (labeled U to indicate likely unsulfation). Other than this, the sequences of WT ACKR2 and mutant 1 are
identical.B, flowcytometric assessment of the expression levels ofWTACKR2 (blue line) andmutant 1 (red line) in stable transfectedHEK cells. Theproteinswere
measured using anti-HA antibodies to detect the HA tag at the extremeN terminus. Levels of expression are reflected in the extent of the right shift in the flow
cytometry profile. Isotype control antibodies demonstrate the low level of nonspecific antibody staining (green line). C, flow cytometric profiles showing the
internalization of Alexa-CCL2 by untransfected HEK cells (panel i), HEK cells expressingWT ACKR2 (panel ii), and HEK cells expressingmutant 1 (Mut1; panel iii).
Note the prominent right shift in panel ii indicative of Alexa-CCL2 binding and uptake compared with the more limited right shift apparent in panel iii. D,
summary of mean fluorescence intensity values obtained from binding/internalization of the indicated concentrations of Alexa-CCL2 by HEK cells expressing
either WT ACKR2 or mutant 1. Note that untransfected HEK cells display a very low mean fluorescence intensity value indicative of low levels of nonspecific
Alexa-CCL2binding. Thedatawere analyzedusingone-wayANOVAwith Tukey’s post-test. E,Westernblot analysis of CCL2degradationover 24h. Biotinylated
CCL2 was incubated in the presence of HEK cells expressing either WT ACKR2 or mutant 1 (results from two clones shown), and the levels of intact CCL2
remainingwere assessed usingWestern blotting and detection by streptavidin-HRP. Note the reduction in biotinylated CCL2 levels bywild type CCR2 but not
by either of the two clones of mutant 1.
Characterizing a Ligand-bindingMotif in ACKR2
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chlorate to reduce ligand binding and internalization by
ACKR2, we tested higher concentrations. As shown in Fig. 3C
(panel i), although concentrations of sodium chlorate as high as
100mMpartially reduced ligand binding byACKR2, concentra-
tions of 150 mM induced a considerably more marked and sig-
nificant reduction. This was also shown by flow cytometry (Fig.
3C, panel ii) andWestern blotting (Fig. 3C, panel iii). Thus both
mutation of N-terminal tyrosine residues and treatment of
ACKR2-expressing cells with high concentrations of sodium
chlorate demonstrate the involvement of tyrosine sulfation in
ligand binding and internalization by ACKR2.
Tyrosylsulfotransferases 1 and 2 Are Involved in ACKR2
Sulfation—Tyrosine sulfation is dependent on the expression
of tyrosylsulfotransferases, of which two are known to be
expressed and functioning in mammalian cells (45). To gain
insights into which of these may be involved in ACKR2 sulfa-
tion, we examined their expression in tissues either associated
with, or not associated with, ACKR2 expression. As shown in
Fig. 4A, although very little expression of TPST1 was detected
in any of the cell types examined, the strongest expression of
TPST2 was detected in lymphatic endothelial cells and pla-
centa, both sites of highACKR2 expression (15–17), suggesting
that TPST2 may contribute to tyrosine sulfation in ACKR2.
Further analysis of TPST1 and TPST2 in HEK and HEK-
ACKR2 cells revealed equivalent expression of both enzymes at
themRNA (Fig. 4B, panel i) and protein (Fig. 4B, panel ii) levels.
To examine the importance of these tyrosylsulfotransferases
for ACKR2 sulfation and function in transfected HEK cells, we
pretreated HEK cells with siRNA to either, or both, enzymes
and then transiently transfected these cells with ACKR2 and
measured ligand binding (using Alexa-CCL22) 24 h later. As
shown in Fig. 4C (panel i), treatment with siRNA to either
enzyme individually had no significant effect on ligand binding
by ACKR2; however, simultaneous treatment with siRNA to
FIGURE 3. Inhibition of protein sulfation significantly inhibits ACKR2 activity. A, Western blot analysis of ACKR2 sulfation. Anti-HA beads were used to
immunoprecipitate ACKR2 from a clone of HEK cells expressing WT ACKR2 and from a pool of HEK cells expressing mutant 1, as well as from two separately
derived clones of mutant 1 transfectants. The 50-kDa molecular mass marker, which is coincident with migration of ACKR2 in SDS-PAGE gels, is shown in the
upper panel. Expression was detected using an anti-sulfotyrosine antibody and loading normalized by reprobing the blot with an anti-HA antibody (lower
panel). The 40- and 50-kDa molecular mass markers are indicated in the lower panel. B, mean fluorescence intensity values derived from flow cytometric
assessment of Alexa-CCL22 binding toACKR2-expressingHEK cells grown in either normalmediumormedium supplementedwith 30mM sodiumchlorate for
the indicated times. The data were analyzed using one-way ANOVA with Tukey’s post test. C, panel i, mean fluorescence intensity values measuring Alexa-
CCL22 binding to ACKR2-expressing HEK cells treatedwith the indicated increasing concentrations of sodium chlorate. The graph also includesmeasurement
of mean fluorescence intensity of Alexa-CCL22 binding to nontreated ACKR2 expressing HEK cells (Non-treated) and nontreated untransfected HEK cells
(Non-treated Neg). Panel ii, flow cytometric profile demonstrating the reduction in Alexa-CCL22 binding by ACKR2-expressing HEK cells before (blue line) and
after (red line) treatment for 6 h with 150 mM sodium chlorate. Panel iii, Western blot analysis of lysates of cells expressing ACKR2 using anti-sulfotyrosine
antibodies. Cells were either left untreated or treated for 6 days with 150 mM sodium chlorate. The 40- and 50-kDamolecular mass markers are indicated. Gel
loading was normalized by reprobing with antibodies to -actin (lower panel).
Characterizing a Ligand-bindingMotif in ACKR2
MAY 2, 2014•VOLUME 289•NUMBER 18 JOURNAL OF BIOLOGICAL CHEMISTRY 12335
 at G
lasgow
 U
niversity Library on M
ay 9, 2014
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
both enzymes significantly reduced ligand binding. This treat-
ment was not associated with any reduction in ACKR2 protein
expression (Fig. 4C, panel ii) and suggests that both enzymes
are independently able to contribute to sulfation of and there-
fore ligand binding by ACKR2.
No Single Tyrosine Residue Is Essential for Ligand Binding by
ACKR2—We next performed more specific mutagenesis stud-
ies in which individual tyrosines within the conserved motif
were mutated to phenylalanines (mutants detailed in Table 3).
As is apparent from Fig. 1, only three of the tyrosines, tyrosines
1, 3, and 4, are conserved. Tyrosine 2 is unique to higher order
primates. Each of the four tyrosines were separately mutated to
phenylalanines (mutants 2–5), and the resulting HA-tagged
cDNAswere stably transfected intoHEK cells. As shown in Fig.
5A, flow cytometry for the HA tag revealed similar levels of cell
surface expression of each of the fourmutants. As above, ligand
internalization was assessed by flow cytometry to examine the
ability of the WT and mutant variants to take up Alexa-CCL2.
Quantitation of multiple flow cytometry experiments (Fig. 5B)
demonstrated again the profound inability of mutant 1, the full
tyrosine variant of ACKR2, to internalize ligand. These data
further demonstrated that mutation of the individual con-
served tyrosine residues did not significantly impair ligand
internalization compared with the WT receptor. In contrast,
and as shown in Fig. 5C, phenylalaninemutation of the noncon-
served tyrosine residue found in human ACKR2 (mutant 5) in
fact led to significantly enhanced ligand internalization, sug-
gesting that this may represent an evolutionary adaptation in
human ACKR2 that alters the ability of ACKR2 to bind ligand.
Next we carried out the reciprocal experiment in which we
introduced individual tyrosines into the fully tyrosine mutated
variant of ACKR2 (mutant 1) to see whether single tyrosine
residues were sufficient to rescue ligand internalization by this
mutant. These mutants were stably transfected into HEK cells
as above, and as shown in Fig. 5D, the transfectants displayed
similar expression levels as assessed by flow cytometry for the
incorporated HA tag. In ligand binding and internalization
studies, again using Alexa-CCL22 (Fig. 5E), it was clear that
introduction of the single residues into the fully mutated motif
is sufficient to at least partially rescue ligand uptake by ACKR2.
FIGURE 4.Analysis of roles for tyrosylsulfotransferases 1 and2 (TPST1 and2) inACKR2 sulfation.A, RT-PCR analysis of the expression of TPST1 and TPST2
in the indicated cell types. Expression is reportedasnumberof transcripts per 10,000 copies of TATA-bindingprotein (TBP). HD-LECs arehumandermal-derived
lymphatic endothelial cells. B, panel i, RT-PCR analysis of TPST1 and TPST2 expression in untransfected andACKR2-transfectedHEK cells. Expression is reported
as number of transcripts per 1,000 copies of TATA-binding protein. ACKR2 transcript levels are also shown to indicate the high expression levels in transfected
HEK cells. Panel ii, Western blot analysis of TPST1 and TPST2 protein expression in untransfected (HEK) and ACKR2 transfected (HEK ACKR2) cells. TheWestern
blotswere normalizedby reprobingwith antibodies to-tubulin.C,panel i, effects of siRNA to TPST1 and TPST2on ligandbindingbyACKR2 in transfectedHEK
cells. The data are reported as mean fluorescence intensity values (MFI) of Alexa-CCL22 binding as measured using flow cytometry. Cells were treated either
with siRNA to TPST1 and/or TPST2 orwith a scrambled control siRNA.Mean fluorescence intensity values derived fromAlexa-CCL22 treated untransfectedHEK
cells are included for comparison. Panel ii, densitometric analysis of ACKR2 expression in HEK cells treated as indicated in Fig. 4C (panel i) and normalized to
-actin.
TABLE 3
Summary of ACKR2mutants generated
Name Description
Predicted
N-terminal
sulfation status
Protein
sequence of
tyrosine region
Wild type All tyrosines present S-S-S-X-S YYYDY
Mutant 1 All tyrosines mutated U-U-U-X-U FFFDF
Mutant 2 First tyrosine mutated U-S-S-X-S FYYDY
Mutant 3 Third tyrosine mutated S-S-U-X-S YYFDY
Mutant 4 Fourth tyrosine mutated S-S-S-X-U YYYDF
Mutant 5 Second tyrosine mutated S-U-S-X-S YFYDY
Mutant 6 Only first tyrosine present S-U-U-X-U YFFDF
Mutant 7 Only second tyrosine present U-S-U-X-U FYFDF
Mutant 8 Only third tyrosine present U-U-S-X-U FFYDF
Mutant 9 Only fourth tyrosine present U-U-U-X-S FFFDY
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Thus together these data demonstrate that although tyrosine
residues are essential for efficient ligand internalization, this
cannot be accounted for on the basis of a single tyrosine residue
within the conservedmotif. Indeed, the fact that reintroduction
of single tyrosines was not sufficient to fully reconstitute ligand
binding and internalization indicates a requirement for multi-
ple N-terminal tyrosine resides for full ACKR2 function.
ASulfatedN-terminal PeptideDerivative of ACKR2 Is Able to
Bind Ligand—To further examine the importance of tyrosine
residues and sulfation status for the ability of the N terminus of
ACKR2 to interact with ligand, we generated a 35-amino acid
peptide (ACKR2-N) corresponding to the extreme N terminus
of ACKR2 (Fig. 6A). Two versions were generated: one was
sulfated on tyrosine residues (ACKR2-N(s)), and the other was
left unsulfated (ACKR2-N(un-s)). The sulfated variantwas gen-
erated by tyrosine sulfation post-peptide synthesis, which
yielded peptide species displaying variable tyrosine sulfation
patterns (Fig. 6B, panels i and ii). Initial assessment of the ability
of the sulfated peptide to bind ligand involved the use of bioti-
nylated chemokine ligands and streptavidin beads to measure
the ability of ligand to interact with and therefore pull down the
ACKR2 peptides. This assay involves the eventual detection by
Western blotting of the peptide using anti-ACKR2 antibodies.
As shown in Fig. 6C (panel i) and as quantified by densitometry
in Fig. 6C (panel ii), although biotinylatedCCL2was able to pull
down the sulfated ACKR2-N peptide (lane 1), this was not seen
to the same extent with biotinylated CCL19 (lane 2), a homeo-
static CC-chemokine that does not bind to ACKR2. In fact the
amount of ACKR2-N pulled down by biotinylated CCL19 was
no greater than that pulled down by nonspecific interaction of
ACKR2 with the streptavidin beads (lane 3). These data there-
fore confirm the relative selectivity of the peptide for inflamma-
tory CC-chemokines.
Next we examined the ability of the peptide, in both sulfated
and unsulfated forms, to interfere with the ability of the inflam-
matory CC-chemokine CCL2 to bind to either ACKR2 (in het-
erologous transfectants) or to its cognate signaling receptor
CCR2 (inTHP1 cells). As shown in Fig. 6D, the sulfated peptide,
FIGURE 5. Individual tyrosine residues do not account for the ligand internalizing activity of ACKR2. A, flow cytometric assessment, using anti-HA
antibodies, of the expression levels ofmutants 2–5 in the transfectedHEK cells. Note that the extent of the right shift of the flow cytometric profile is indicative
of the extent of expression of the mutants. B, summary of mean fluorescence intensity values obtained from flow cytometric analysis of the binding of
Alexa-CCL2 to WT ACKR2 and mutants 1–4. Note again that untransfected HEK cells do not significantly bind Alexa-CCL2. C, summary of mean fluorescence
intensity values obtained from flow cytometric analysis of the binding of Alexa-CCL22 to mutant 5 compared with untransfected HEK cells and WT ACKR2-
expressing HEK cells. D, flow cytometric assessment using anti-HA antibodies of the expression levels of mutants 1 and 6–9 in the transfected HEK cells. E,
summaryofmean fluorescence intensity valuesobtained fromflowcytometric analysis of thebindingofAlexa-CCL22 toWTACKR2,mutant 1, andmutants 6–9
all expressed in HEK cells. Note again that untransfected HEK cells do not significantly bind Alexa-CCL22. All data were analyzed using one-way ANOVA with
Tukey’s post test.
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but importantly not the unsulfated peptide, was able to signifi-
cantly impair binding and internalization of Alexa-CCL2 by
ACKR2 transfected HEK cells. In addition, the sulfated peptide
was able to significantly impair the binding of Alexa-CCL2 to
CCR2onTHP1 cells (Fig. 6E). Notably, the ability of the peptide
to inhibit ligand internalization by ACKR2 was unaffected by
precomplexing with ligand (Fig. 6D). Importantly this precom-
plexing also did not enhance the neutralizing activity of the
unsulfated peptide. Thus a sulfated peptide derived from the
ACKR2 N terminus is capable of inhibiting ligand interactions
with ACKR2 and its cognate signaling receptor, CCR2.
Staphopain ACan Cleave the ACKR2NTerminus—Wehave
previously reported that, in heterologous transfectants, ACKR2
is subject toN-terminal processing giving rise to a 38-kDa trun-
cated receptor that has lost approximately the equivalent of the
35-amino acid peptide generated in this study (44). There have
been previous reports of pathogen-derived proteolytic enzymes
cleaving the N termini of chemokine receptors, and in particu-
FIGURE 6. A sulfated peptide derived from the ACKR2 N terminus binds ligand. A, sequences of peptides designed from the N terminus of ACKR2 and
generated by peptide synthesis. SUL* indicates a sulfatable tyrosine residue. ACKR2-N(s) represents the sequence of the fully sulfated peptide whereas
ACKR2-N(un-s) indicates a fully unsulfated peptide. The hexahistidine tags are indicated at the extreme C terminus of the peptide. B, mass spectrometry
analysis of the mixed levels of sulfation apparent in the sulfated version of ACKR2-N. The mass/charge (m/z) profile is shown in panel i, and the deconvoluted
molecular mass profile is shown in panel ii. Prominent m/z peaks are indicated in panel i, and the molecular mass peaks corresponding to the differentially
sulfated peptide variants are indicated in panel ii. In panel ii, the extent of sulfation of the different variants is indicated in parentheses after themolecularmass.
C, Western blot analysis (panel i) using an anti-ACKR2 antibody and subsequent densitometry analysis (panel ii) indicate the presence of ACKR2-N(s) after
pulldown binding assays using biotinylated-CCL2. As shown, the ACKR2 peptide migrates as two bands of 8 and 14 kDa. Note the markedly higher pulldown
of theACKR2peptidebybiotinylatedCCL2 (lane1) comparedwithbiotinylatedCCL19 (lane2). ThepulldownachievedbybiotinylatedCCL19 is not significantly
different from the background binding of ACKR2-N(s) to the streptavidin beads used for the pulldown (lane 3). Note also the lack of nonspecific antibody
cross-reacting with 4 g of CCL2, confirming the specificity of the antibody in this assay. D, addition of sulfated ACKR2 peptide (ACKR2-N(s)), but not the
unsulfated ACKR2 peptide (ACKR2-N(un-s)), significantly reduced uptake of Alexa-CCL2 by transfected HEK ACKR2 cells, as determined by flow cytometric
analysis (data are reported as mean fluorescence intensity values from the flow cytometric analysis). The data were analyzed using one-way ANOVA with
Tukey’s post test. E, addition of ACKR2-N(s) significantly reduced uptake of Alexa-CCL2 by CCR2 expressed on THP1 cells, as determined by flow cytometric
analysis. AF-CCL2 only refers to THP1 cells exposed to Alexa-CCL2, and AF-CCL2ACKR2-N(s) refers to THP1 cells exposed to Alexa-CCL2 as well as the sulfated
N-terminal peptide. The data were analyzed using Student’s t test.
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lar the important role of proteases such as staphopain A has
been highlighted in this regard (46).We therefore exposedHEK
cells expressing ACKR2 to staphopain A and observed the
effects on ACKR2 over a range of time points up to 2 h. Because
we were looking for N-terminal truncation, previously pub-
lished anti-ACKR2 monoclonal antibodies and anti-HA tag
antibodies were inappropriate because their recognition sites
would have been lost. We therefore used a polyclonal antibody
that detects theACKR2C terminus and thatwe have previously
characterized in a range of contexts (18, 22). As shown in Fig.
7A and quantified in Fig. 7B, HEK cells expressing ACKR2 pro-
duced a variety of full-length and truncated variants detected
using this antibody. Importantly one of these variants of 38
kDa, equivalent to the size observed previously for truncated
ACKR2, appeared in increasing amounts following exposure of
the cells to staphopain A. Attempts to formally confirm the
molecular nature of the truncated species using mass spec-
trometry were unsuccessful, possibly because of the previously
reported difficulties in obtaining mass spectrometry data from
ACKR2 (44). In addition a number of approaches aimed at try-
FIGURE 7. The serine protease staphopain A cleaves ACKR2 at the N terminus. A, ACKR2 expressed on HEK cells is cleaved by staphopain A (Staph A) as
determined by Western blot analysis using an antibody specific for the C terminus of ACKR2. In this experiment -tubulin was used as a loading control.
Full-length (*) and truncated (** and ***) ACKR2 proteins are indicated. ACKR2-expressing HEK cells were treated either with PBS or with staphopain A for the
indicated time points. Untransfected HEK cells treatedwith staphopain A are included as a negative control. The gel positions corresponding to 40, 50, and 60
kDa are indicated. B, densitometric analysis of band intensity from the blot shown inA.NEG refers to the PBS-treatedACKR2-transfectedHEK cells. In this figure
the full-lengthACKR2 ismarkedwith *, and the truncatedACKR2 ismarkedwith *** inA. Expression levels are normalized to the-actin loading control.C, flow
cytometric assessment of the effects of staphopain A on Alexa-CCL22 internalization by ACKR2-expressing HEK cells. The data are presented as mean
fluorescence intensity values measured from flow cytometric analysis of Alexa-CCL22 binding. HEK-AF-CCL22 represents the levels of Alexa-CCL22 binding to
untransfected HEK cells. ACKR2-PBS represents the background fluorescence of ACKR2 transfected HEK cells. ACKR2-AF-CCL22 represents the binding of
Alexa-CCL22 toACKR2-transfectedHEK cells.ACKR2-AF-CCL22/Staph. A (2mM) represents cells pretreatedwith 2M staphopainAprior toAlexa-CCL22binding.
Note, in this experiment, that the alternative ACKR2 ligand, CCL22, is used in place of CCL2. The data were analyzed using one-way ANOVA with Tukey’s post
test. D, panel i, flow cytometric profiles showing the expression of ACKR2 in untransfected (upper panel) and transfected (lower panel) CHO cells. ACKR2
expression levels were measured using anti-HA antibodies. The right shift of the flow cytometric profile for CHO-ACKR2 cells indicates high level expression.
Panel ii, measurement of Alexa-CCL22 (AF-CCL22) binding to ACKR2-expressing CHO cells in the presence, or absence, of increasing concentrations of staph-
opain A. The data were obtained by measuring fluorescence intensity in a standard fluorescent plate-reader. Background fluorescence is shown by the data
labeled untreated. The data presented in this figure are representative of more than two repeat experiments.
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ing to purify theN-terminal peptide released after staphopainA
treatmentmet with similar difficulties, which we presume to be
a consequence of the low concentrations of peptide produced.
Importantly, however, in agreement with the N-terminal trun-
cation, a modest but significant staphopain A-dependent
reduction in ACKR2 ligand (Alexa-CCL22) uptake activity was
detected in staphopain A-treated HEK-ACKR2 cells using flow
cytometry (Fig. 7C). To confirm this in a separate cell line, we
transfectedCHOcells withACKR2 (Fig. 7D, panel i) and exam-
ined ligand binding and internalization following treatment
with 0.5 and 2 M staphopain A. In these experiments, ligand
binding and uptake were assessed using a fluorescence-based
assay adapted for 96-well plate format. As shown in Fig. 7D
(panel ii), staphopain A treatment resulted in more marked
inhibition of ligand uptake and internalization in this cell line
than was seen with the transfected HEK cells. Specifically, at 2
M, staphopain Awas able to reduce ligand binding and uptake
by ACKR2-expressing CHO cells by 50%. These data there-
fore suggest thatACKR2 is a natural substrate for staphopainA,
which results in cleavage of the ACKR2 N terminus.
DISCUSSION
Although a large number of studies have described the
importance of tyrosine sulfation for chemokine receptor ligand
binding and function, there have been few studies (47) into the
importance of similar sulfated tyrosine motifs for atypical
chemokine receptor function. This is important because atyp-
ical chemokine receptors are biochemically distinct from the
signaling chemokine receptors and also typically display non-
leukocyte-based expression patterns. Here we demonstrate
that a conserved tyrosine motif in the N terminus of ACKR2 is
essential for ligand internalization and scavenging and that
within this motif, multiple tyrosines are required for efficient
ligand uptake. Thus the importance of this motif is maintained
in the atypical chemokine receptor subfamily. Formal demon-
stration of the importance of sulfation of these tyrosine residues
is presented in the form of sodium chlorate inhibition. Growth
of HEK cells expressing ACKR2 in the presence of chlorate
significantly reduced ligand internalization by ACKR2. How-
ever, this was incomplete at concentrations of sodium chlorate
typically used in such experiments (30 mM), and this probably
relates to the extremely long half-life of the ACKR2 protein (13,
48). Notably, use of higher concentrations of sodium chlorate
(150 mM) resulted in more substantial and highly significant
inhibition of ligand uptake and internalization by ACKR2-ex-
pressing HEK cells. Importantly the roles played by sulfated
tyrosines are further confirmed by the use of peptides derived
from the ACKR2 N terminus. Notably a sulfated variant of the
peptide is able to bind ligand and thereby inhibit ligand binding
to ACKR2 or the signaling receptor CCR2, whereas the unsul-
fated variant is not. The ability of a peptide from the ACKR2 N
terminus to bind ligand suggests that this site is of general
importance for chemokine ligand binding to receptors because
similar peptides from other conventional chemokine receptors
also display ligand binding properties (33, 38, 49, 50). Overall,
these data indicate that the sulfated tyrosine motif is essential
for ACKR2 function and that a peptide derived from this area is
able to bind ACKR2 ligands.
We have previously reported that, in cells expressing ACKR2,
the protein is detected in two processed forms. The first is the
full-length protein, and the second is an N-terminal variant trun-
cated by35 amino acids.Wehave proposed that thismay repre-
sent shedding, from the seven-transmembrane base of ACKR2,
of a peptide capable of binding ACKR2 ligands and such a func-
tion of this peptide is supported by the current study. This pep-
tidemay therefore act in the vicinity of ACKR2-expressing cells
as a motile blocker of inflammatory CC-chemokine function.
Thus farwe have not identified anymammalian proteases capa-
ble of generating such a peptide from intact ACKR2. However,
previous reports of the ability of bacterially derived proteases to
cleave the N terminus of other chemokine receptors, most
notably CXCR2 (46), prompted us to examine whether such
proteases can also cleave the ACKR2N terminus. Here we pro-
vide evidence of truncation of ACKR2 by the Staphylococcus
aureus protease staphopain A to yield an N-terminally trun-
cated variant of 38 kDa. In keeping with the importance of
this region for ligand binding, staphopain A treatment of
ACKR2-expressing cells also significantly reduced ligand inter-
nalization. This reduction was modest in ACKR2-expressing
HEK cells but was considerably more marked in ACKR2-ex-
pressing CHO cells. These differencesmay relate to the relative
recycling ability of ACKR2 from the extensive intracellular
stores in HEK cells and CHO cells but may also be explained by
differences in cell surface glycocalyx density and thus access for
the enzyme toACKR2.Despite this functional evidence of trun-
cation, which supports the Western blot data, attempts at
obtaining mass spectrometry confirmation of the molecular
nature of the truncated ACKR2 product were unsuccessful.We
have previously reported difficulties in mass spectrophotomet-
ric analysis of ACKR2 (44) and propose that this is likely to be
the reason for the current difficulties and may relate to the
specific nature of the truncated product resulting from
staphopain A treatment. In addition we used a number of
approaches to try to identify the released N-terminal peptide
including immunoprecipitation with anti-HA antibody. Again
this proved unsuccessful, suggesting either that the concentra-
tion of released peptide was very low or that the peptide was
further degraded in the culture medium. Assuming the ability
of staphopain A to release an intact N-terminal peptide from
ACKR2, the question then is why might a bacterially derived
protease wish to cleave theN terminus of ACKR2? Cleaving the
N terminus of CXCR2 makes sense because this will neutralize
neutrophilmigration overwhich, with the exception perhaps of
some murine contexts (51), ACKR2 has little influence. The
possible reason for staphopain A cleavage of ACKR2 is that this
will, in fact, complement the CXCR2 cleavage by yielding small
peptide inhibitors of inflammatory CC-chemokine function,
thereby preventing recruitment of myelomonocytic inflamma-
tory leukocytes. Importantly, although the overall impairment
of ACKR2 function associated with staphopain A cleavage was
modest, this may be of little concern to the pathogen if gener-
ation of small amounts of N-terminally derived peptide is all
that is required.
The ability of theACKR2-derived peptide to inhibit the bind-
ing of CCL2 to its cognate receptor, CCR2, suggests that this
may have some therapeutic benefit. This would be particularly
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important if the ACKR2-derived peptide was able to bind all
ACKR2 ligands. Notably, despite it being over two decades
since the initial cloning of chemokine receptors, there are no
small molecule blockers of chemokine receptor function
licensed for use in inflammatory pathologies. This inability to
therapeutically utilize inflammatory chemokine receptor
blockers most likely reflects the highly redundant nature of the
inflammatory chemokine response (52, 53). In terms of inflam-
matory CC-chemokines, many are produced simultaneously at
inflamed sites. This is why the promiscuity of ACKR2 and its
ability to internalize and scavenge all inflammatory CC chemo-
kines make it such an efficient neutralizer of inflammatory CC-
chemokine function. The advantage of the N-terminal peptide
over individual smallmolecule receptor-blockers would lie pre-
cisely in its ability to neutralize the activity of multiple different
inflammatory CC-chemokines. This is the strategy adopted by a
number of viral species (42), and the proper therapeutic advance-
ment of such a strategy may be of major importance in the devel-
opment of novel anti-inflammatory therapeutics. However, the
ACKR2-derived peptide in its current form does not yet display
sufficient affinity for ligand tomerit in vivo testing.
In conclusion, therefore, we provide for the first time evi-
dence of the importance of N-terminal tyrosine residues for
ACKR2 function. We highlight this area as being essential for
ligand internalization and scavenging and demonstrate the
ability of a peptide derived from this region to bind inflamma-
tory CC-chemokines.
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